PUBLIC COMPANY
saveAstellas Pharma Inc
updated 3mo ago
Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. .
community read0 votes
🐶 often sniffed alongside
top 5pipeline
8
marketed
1
phase 3
0
catalysts ytd
1
approvals ytd
1
recalls ytd
0
Pipeline(8)
pipeline depth8 products
4Phase 21Marketed3Unknown
Marketed
enfortumab vedotin
Muscle Invasive Bladder Cancer (MIBC)
Nectin-4Tubulin
Phase 2ASP-2957
X-Linked Myotubular Myopathy (XLMTM or MTM)
Phase 2ASP-7316
Juvenile Macular Degeneration (Stargardt Disease)
Phase 2zocaglusagene nuzaparvovec
Pompe Disease
Phase 2zolbetuximab
Metastatic Adenocarcinoma of The Pancreas
Claudin-18
drugIZERVAY
drugPADCEV
drugXTANDI
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through Menopause
- phase4A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration
- phase1A Study of ASP3082 in Adults With Advanced Solid Tumors
- phase2A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke
- phase1A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- phase3A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
- phase3A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause
- —Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis
🐶 Hiring Signal
News
- nChroma halves workforce, BioXcel lets execs goFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 1h ago
- Novo submits sickle cell drug; Flagship, Gates Foundation deepen tiesNovo views the medicine, acquired in a billion-dollar deal, as a future blockbuster. Meanwhile, a pair of startups forged an RNA editing pact and Astellas lined up two new trials in pancreatic cancer.biopharma_dive · 6d ago
- With MFN now embedded in pharma, execs see little impact from Democrats’ blue waveSpeaking on third quarter earnings calls this week, Novo and Pfizer’s CEOs see little change to their Most Favored Nation drug pricing deals, which were signed with the Trump administration last year.biospace · 15d ago
- Lilly shuffles business structure; Novartis writes off part of Avidity dealLilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on what it believes to be a “best-in-class” cancer immunotherapy prospect.biopharma_dive · 22d ago
- Astellas bets up to $1.34B for option to advance Audax immuno-oncology assetAstellas Pharma could secure the exclusive global rights to Audax Biosciences’ DAX-044, an antibody-cytokine fusion therapy that activates the immune system in the vicinity of the tumor.biospace · 22d ago
- Astellas makes $1.3B bet on Audax’s preclinical push to reverse decades of IL-12 woesAstellas has struck a deal for Audax Biosciences’ IL-12 program, committing up to $285 million in upfront and option fees to secure a chance to license the preclinical immuno-oncology program.fiercebiotech · 22d ago
- Astellas links up with AI Proteins in $400M computational drug discovery dealJapan's Astellas Pharma has tapped Boston computational discovery company AI Proteins in a drug discovery deal potentially worth $400 million.fiercebiotech · 29d ago
- Exclusive: Astellas partners with Boston ‘miniproteins’ startupChris Bahl believes AI can help make tiny proteins capable of doing things that bigger and more traditional proteins like antibodies struggle to do. And now the Japanese drugmaker Astellas is buyin…endpoints · 1mo ago
- J&J earnings set ‘negative tone’; Shkreli vs. the FTCA 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech’s bid for a product expansion fell short.biopharma_dive · 1mo ago
- From Scientific Hypothesis to Clinical Practice: The Next Chapter for CLDN18.2Astellas reflects on a decade of progress in CLDN18.2 and the opportunities ahead in patient identification, testing and innovationfiercebiotech · 1mo ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that